J&J’s once-daily pill eases psoriatic arthritis symptoms in late-stage trial

Johnson & Johnson (JNJ) said its once-daily pill eased symptoms in more patients with psoriatic arthritis than a placebo in a late-stage trial, potentially supporting expanded use of the drug.
The company said 58 per cent of patients who took icotrokinra, branded as Icotyde, achieved a 20 per cent improvement in tender and swollen joint counts, alongside improvements in other measures of disease activity, after 16 weeks. That compared with 41 per cent of those who received a placebo in the 552-patient trial. J&J said no new safety concerns were identified.
Among patients with sufficient skin involvement, 57 per cent had clear or nearly clear skin after 16 weeks, compared with 14 per cent on placebo.
Psoriatic arthritis is a long-term inflammatory condition that causes joint pain, swelling and stiffness. Icotyde is already approved by the Food and Drug Administration for moderate-to-severe plaque psoriasis.
The results mark another advance for the oral peptide, which Wall Street analysts have tipped as J&J’s next blockbuster with the potential to take share from established rivals. The company expects peak sales to top $5bn across multiple indications.
Unlike injectable biologics such as AbbVie’s (ABBV) Skyrizi and UCB’s (UCB) Bimzelx, Icotyde is taken orally, which would offer a more convenient option if approved. The psoriatic arthritis market is nonetheless highly competitive, with oral treatments including Bristol Myers Squibb’s (BMY) Sotyktu and Amgen’s (AMGN) Otezla already available.
David Lee, J&J’s global immunology head, said “patients don’t want to be overtreated, they want a treatment that fits them where they’re at”. He added that about 30 per cent of patients with psoriasis also have psoriatic arthritis, highlighting a significant unmet need.
The trial enrolled adults with active psoriatic arthritis who had not previously been treated with biologic medicines.
